AFP and hepatocellular carcinoma: obtained an HLA-A2+/AFP-specific TCR (191), and a clinical trial of this TCR-T cell population for HCC is underway to confirm its effectiveness in treating HCC by examining AFP expression and T-cell infiltration in biopsied tissues (NCT03132792).